AI in Oncology Market Size & Share 2026-2035

AI in Oncology Market Size

The global AI in oncology market was valued at USD 3.1 billion in 2025 and is projected to grow from USD 3.7 billion in 2026 to USD 32 billion by 2035, expanding at a CAGR of 27.2%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by numerous factors, such as rising demand for early detection and classification of cancer, increasing prevalence of cancer, and growing adoption of precision medicine.

AI in oncology refers to the use of artificial intelligence technologies to enhance cancer detection, diagnosis, treatment planning, and drug discovery. It leverages data analytics, imaging, and machine learning to improve accuracy, efficiency, and patient outcomes in oncology care.

Leading companies in the AI in oncology market include Tempus, Flatiron Health (Roche), NVIDIA, Guardant Health, and Paige AI. These companies are strengthening their market presence by advancing AI-driven platforms for cancer detection, diagnosis, and treatment optimization. They are focusing on enhancing data analytics capabilities, expanding clinical collaborations, and integrating real-world evidence into oncology workflows. Additionally, they are investing in high-performance computing, genomic analysis, and digital pathology solutions to improve clinical outcomes and operational efficiency. Strategic partnerships with healthcare providers, research institutions, and pharmaceutical companies are further supporting innovation, scalability, and broader adoption of AI technologies across global oncology care settings.

The market has increased from USD 1.9 billion in 2022 and reached USD 2.6 billion in 2024, with a historic growth rate of 17.1%. The increasing prevalence of cancer is a critical driver accelerating the adoption of artificial intelligence (AI) in oncology. According to the National Institutes of Health (NIH), cancer remains one of the leading causes of death worldwide. In 2022 alone, nearly 20 million new cancer cases were reported globally, alongside approximately 9.7 million cancer-related deaths. This growing disease burden is placing immense pressure on healthcare systems, clinicians, and diagnostic infrastructure, highlighting the urgent need for more efficient and scalable solutions. AI technologies are increasingly being deployed to address these challenges by enhancing early detection, improving diagnostic accuracy, and enabling personalized treatment planning.

With the rapid rise in cancer incidence, particularly driven by aging populations, lifestyle changes, and environmental factors, traditional oncology workflows are becoming insufficient to manage the volume and complexity of cases. AI-powered tools, such as imaging analytics and predictive algorithms, can significantly reduce diagnostic delays and optimize patient outcomes.Consequently, the escalating prevalence of cancer is a major factor propelling investment and innovation in AI-driven oncology solutions globally.

Additionally, the rising demand for early detection and precise classification of cancer is a significant driver for the adoption of artificial intelligence (AI) in oncology. Early diagnosis plays a crucial role in improving survival rates, reducing treatment costs, and enhancing patient outcomes. However, traditional diagnostic methods often face limitations such as variability in interpretation, delayed results, and challenges in detecting cancers at an early stage. AI-powered technologies, particularly in medical imaging and pathology, are increasingly being utilized to address these gaps by enabling faster and more accurate detection of tumors.

Advanced algorithms can analyze large volumes of clinical data, identify subtle patterns, and classify cancer types with high precision. This supports clinicians in making timely and informed decisions. As awareness around preventive healthcare grows and screening programs expand globally, the need for efficient and scalable diagnostic solutions continues to rise. Therefore, the increasing emphasis on early detection and accurate cancer classification is driving the integration of AI solutions in oncology workflows.

AI in Oncology Market Trends

• The growing adoption of precision medicine is a key driver accelerating the integration of artificial intelligence (AI) in oncology. Precision medicine focuses on tailoring treatments based on individual patient characteristics, including genetic profiles, lifestyle factors, and disease progression. AI plays a vital role in analyzing complex biological data, enabling more targeted and effective therapeutic strategies.
• Additionally, the increasing availability of genomic and molecular data has strengthened the demand for advanced analytical tools. AI algorithms can process vast datasets to identify biomarkers, predict treatment responses, and support personalized drug development. This significantly enhances clinical decision-making and reduces the trial-and-error approach in cancer treatment.
• Moreover, advancements in technologies such as next-generation sequencing and molecular diagnostics have further amplified the role of AI in precision oncology. These innovations require robust computational capabilities to interpret intricate datasets accurately. AI-driven platforms help bridge this gap by delivering actionable insights efficiently.
• Furthermore, the shift toward patient-centric care and improved treatment outcomes is encouraging healthcare providers to adopt precision medicine approaches. As a result, AI continues to gain traction as a critical enabler, driving innovation and improving survival rates in oncology care.

AI in Oncology Market Analysis

Based on component, the AI in oncology market is segmented into software solutions, hardware, and services. The software solutions segment held the largest share of 42.9% in 2025

• The software solutions segment represents the dominating segment within the market, primarily driven by the increasing reliance on advanced analytics and decision-support systems. These solutions enable efficient processing of large-scale clinical, imaging, and genomic datasets, supporting accurate diagnosis, treatment planning, and outcome prediction in oncology care.
• Additionally, software platforms offer scalability, interoperability, and integration with existing healthcare IT infrastructure, making them essential for clinical workflows. The growing emphasis on data-driven decision-making and personalized medicine continues to strengthen demand for AI-based oncology software across hospitals, research institutions, and diagnostic centers.
• The hardware segment accounted for USD 983.3 million in 2025 and is projected to expand at a CAGR of 26.9% from 2026 to 2035. The hardware segment plays a crucial role in supporting AI deployment in oncology through specialized computing systems and imaging equipment. High-performance processors, GPUs, and dedicated servers are essential for handling complex algorithms and large volumes of medical data, ensuring efficient execution of AI models.
• Moreover, advancements in imaging hardware, such as AI-integrated scanners and diagnostic devices, are enhancing the accuracy and speed of cancer detection.
• The services segment accounted for USD 766 million in 2025 and is projected to expand at a CAGR of 27.2% from 2026 to 2035. The services segment encompasses consulting, integration, maintenance, and training services that facilitate the adoption and optimization of AI solutions in oncology. These services are critical for ensuring seamless implementation, customization, and operation of AI-based platforms within healthcare systems.

Based on application, the market is segmented into cancer detection and diagnosis, treatment planning and optimization, drug discovery, and drug development and clinical trials. The drug discovery segment held the largest industry share of 46.1% in 2025.

• The drug discovery segment is recognized as the dominant application in the AI in oncology market, driven by the need to accelerate the identification of novel cancer therapies. AI technologies facilitate rapid screening of compounds, target identification, and prediction of drug efficacy, significantly reducing the time and cost involved in traditional discovery processes.
• The treatment planning and optimization segment accounted for USD 658.8 million in 2025 and is projected to expand at a CAGR of 27.8% from 2026 to 2035. The treatment planning and optimization segment focuses on enhancing clinical decision-making by leveraging AI to design personalized oncology treatment strategies. AI systems can analyze patient-specific factors, including genetic data and disease progression patterns, to recommend optimal therapeutic approaches.
• Moreover, these solutions enable continuous monitoring and adjustment of treatment plans, improving patient outcomes and minimizing adverse effects. The increasing shift toward personalized care and value-based healthcare models is supporting the adoption of AI-driven treatment planning tools.
• The cancer detection and diagnosis segment accounted for significant revenue in 2025 and is projected to expand at a CAGR of 27.5% from 2026 to 2035. The cancer detection and diagnosis segment represents the significant share in the application in the AI in oncology market, driven by the increasing emphasis on early and accurate identification of malignancies. AI technologies, particularly in imaging and pathology, enable the analysis of large datasets to detect abnormalities with enhanced precision and reduced diagnostic variability.
• Additionally, the integration of AI in radiology and histopathology workflows supports clinicians in improving diagnostic efficiency and reducing turnaround times. The rising adoption of screening programs and the growing burden of cancer cases continue to reinforce the demand for AI-powered detection and diagnostic solutions.

Based on cancer type, the market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, brain tumor, and other cancer types. The breast cancer segment held the largest industry share of 26.8% in 2025.

• The breast cancer segment represents the dominating cancer type in the AI in oncology market, primarily due to the high prevalence and extensive screening initiatives globally. AI technologies are widely applied in mammography and imaging analysis to enhance early detection, improve diagnostic accuracy, and reduce false positives and negatives.
• For instance, according to WHO, breast cancer caused an estimated 670,000 deaths globally in 2022 and was the most common cancer in women in 157 countries out of 185 in the same year. 
• Additionally, AI-driven tools support risk assessment, tumor classification, and treatment planning, enabling more personalized care approaches. The increasing focus on early-stage diagnosis and preventive screening programs continues to drive the integration of AI solutions in breast cancer management.
• The prostate cancer segment accounted for USD 460.2 million in 2025 and is projected to expand at a CAGR of 27.2% from 2026 to 2035. The prostate cancer segment benefits from AI applications in imaging, pathology, and biomarker analysis to improve diagnostic accuracy and risk stratification. AI tools are increasingly used to analyze MRI data and biopsy samples, supporting clinicians in identifying aggressive forms of the disease.
• Furthermore, AI enables personalized treatment planning by integrating patient-specific clinical and genomic data. The growing emphasis on precision medicine is supporting the increased application of AI in prostate cancer care.
• The colorectal cancer segment accounted for USD 383 million in 2025 and is projected to expand at a CAGR of 26.9% from 2026 to 2035. The colorectal cancer segment incorporates AI technologies in endoscopy and imaging to enhance the detection and classification of polyps and lesions. AI-assisted colonoscopy systems improve detection rates and support early intervention strategies.

Based on end use, the market is segmented into hospitals, diagnostic centers, specialty clinics, and other end users. The hospitals segment held the largest share of 46.8% in 2025

• The hospitals segment represents the dominating end use category in the AI in oncology market, driven by the extensive adoption of advanced diagnostic and treatment solutions within large healthcare settings. Hospitals serve as primary centers for cancer diagnosis, treatment, and management, leading to higher integration of AI technologies across imaging, pathology, and clinical decision support systems.
• Additionally, the availability of advanced infrastructure, skilled professionals, and substantial patient inflow enables hospitals to effectively deploy AI-based oncology solutions. The increasing focus on improving clinical outcomes, operational efficiency, and personalized care continues to reinforce the adoption of AI in hospital settings.
• The diagnostic centres segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 27.8% over the forecast period. The diagnostic centres segment plays a critical role in supporting early cancer detection and screening through AI-enabled imaging and pathology solutions. These centres increasingly utilize AI algorithms to enhance accuracy, reduce diagnostic errors, and manage high volumes of patient data efficiently.
• Moreover, the growing demand for preventive healthcare and routine screening programs is driving the integration of AI technologies in diagnostic workflows. This enables faster turnaround times and improved reliability in cancer diagnosis.

North America AI in Oncology Market

The North America region accounted for 40.4% of the market in 2025. The AI in oncology industry in North America is experiencing robust expansion.

• The U.S. market was valued at USD 716 million and USD 838.6 million in 2022 and 2023, respectively. The market size reached USD 1.2 billion in 2025, growing from USD 1 billion in 2024, and is anticipated to grow at a CAGR of 26.9% from 2026 to 2035.
• The increasing prevalence of cancer remains a major growth driver in the region. According to the Centers for Disease Control and Prevention (CDC), the U.S. reported 1,603,844 cancer cases and 602,347 cancer-related deaths in 2020, highlighting the growing disease burden and the need for advanced diagnostic solutions.
• Additionally, the rising demand for early detection and classification of cancer is accelerating the adoption of AI-driven imaging and diagnostic tools across healthcare systems.
• The presence of advanced healthcare infrastructure and high digitalization levels supports seamless integration of AI technologies in oncology workflows.

Europe AI in Oncology Market

Europe AI in oncology industry accounted for USD 670.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Rising demand for early cancer detection and classification is a key driver, supported by strong screening programs. According to Eurostat, cancer accounted for 1.16 million deaths in 2023, representing 23.9% of total deaths in the EU.
• Additionally, the growing adoption of precision medicine across European healthcare systems is driving the integration of AI technologies for targeted treatment approaches.
• Strong regulatory focus on data quality, patient safety, and clinical outcomes is encouraging the deployment of reliable AI-based oncology solutions.
• Moreover, increasing investments in healthcare digitization and research collaborations are supporting innovation and expanding the application scope of AI in oncology.

Asia Pacific AI in Oncology Market

The Asia Pacific region is projected to show a lucrative growth of about 27.9% during the forecast period.

• The increasing prevalence of cancer is a major factor driving market growth. According to the National Institutes of Health (NIH), India recorded approximately 1,461,427 new cancer cases in 2022, with one in nine individuals at risk of developing cancer in their lifetime.
• Additionally, surging advancements in healthcare infrastructure across emerging economies are improving access to diagnostic and treatment technologies.
• Growing awareness regarding early cancer detection is leading to increased adoption of AI-based diagnostic tools and screening programs.
• Furthermore, the expanding focus on digital health and rising investments in AI technologies are supporting the integration of advanced oncology solutions across the region.

Latin America AI in Oncology Market 

The Latin America AI in oncology industry is experiencing robust growth over the analysis timeframe.

• The rising demand for early detection and classification of cancer is driving the adoption of AI-based diagnostic solutions, particularly in urban healthcare centers.
• Additionally, increasing investments in healthcare infrastructure are enabling the deployment of advanced oncology technologies, including AI-powered platforms.
• The growing prevalence of cancer across the region is further contributing to the need for efficient and scalable diagnostic and treatment solutions.
• Moreover, expanding awareness programs and gradual adoption of precision medicine approaches are supporting the uptake of AI in oncology applications.

Middle East and Africa AI in Oncology Market 

The Middle East and Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Increasing prevalence of cancer, coupled with limited access to early diagnostic tools in certain areas, is driving demand for AI-enabled oncology solutions.
• Additionally, ongoing advancements in healthcare infrastructure and expansion of hospital networks are supporting the adoption of digital and AI-based technologies.
• The growing focus on improving early diagnosis and patient outcomes is further encouraging the integration of AI in oncology workflows.
• Moreover, rising investments in healthcare modernization and increasing adoption of precision medicine are expected to support long-term market development across the region.

AI in Oncology Market Share

• The top five players, including Tempus, Flatiron Health (Roche), NVIDIA, Guardant Health, and Paige AI, collectively accounted for approximately 42% share of the AI in oncology industry, driven by advanced AI platforms, strong clinical integration, robust data analytics capabilities, and expanding collaborations across healthcare and research ecosystems to enhance precision oncology applications.
• AI in oncology companies, healthcare technology providers, and research organizations are increasingly focusing on technological advancements to enhance diagnostic accuracy, treatment efficiency, and clinical outcomes. Key areas of focus include the development of advanced AI algorithms for imaging analysis, predictive analytics, and clinical decision support systems. Additionally, advancements in data integration, model training, and validation processes are improving the reliability and performance of AI solutions. Continuous investments in cloud computing, high-performance infrastructure, and data management technologies are ensuring seamless deployment and scalability across hospitals, diagnostic centers, and research institutions.
• Market participants, including AI solution providers, healthcare institutions, and research organizations, are strengthening strategic collaborations to expand the adoption of AI in oncology and enhance its clinical utility. Partnerships with hospitals, data providers, and technology firms are improving data accessibility and supporting the development of robust AI models. Moreover, collaborations with academic and clinical research institutions are facilitating innovation in applications such as early cancer detection, treatment planning, and drug discovery. These initiatives contribute to improved accessibility, optimized workflows, and increased adoption of AI-driven oncology solutions across diverse healthcare settings, thereby supporting overall market growth.

AI in Oncology Market Companies

Few of the prominent players operating in the AI in oncology industry include:

• Aidoc
• Freenome
• Flatiron Health
• GE HealthCare
• Guardant Health
• Ibex Medical Analytics
• Lunit
• Merative
• NVDIA
• Paige AI
• PathAI
• Qure.ai
• Siemens Healthineers
• SOPHiA GENETICS
• Tempus

• Guardant Health

Guardant Health advances its positioning with AI-enabled liquid biopsy solutions, supported by strong clinical adoption, precision oncology focus, and expanding partnerships that facilitate early cancer detection, treatment selection, and continuous disease monitoring.

• Paige AI

Paige AI enhances its market presence through AI-driven digital pathology solutions, supported by validated clinical algorithms, strong deployment across pathology workflows, and increasing collaborations with healthcare institutions to improve diagnostic accuracy and efficiency in cancer care.

AI in Oncology Industry News:

• In January 2024, PathAI launched six additional oncology indications for PathExploreTM, the first structured, standardized, and scalable panel for characterizing the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). This enhancement benefited the company by expanding its utility for researchers and clinicians, facilitating deeper insights into the tumor microenvironment across different cancer types.

The AI in oncology market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Software solutions
• Hardware
• Services

Market, By Cancer Type

• Breast cancer
• Lung cancer
• Prostate cancer
• Colorectal cancer
• Brain tumor
• Other cancer types

Market, By Application

• Cancer detection and diagnosis
• Treatment planning and optimization
• Drug discovery
• Drug development and clinical trials

Market, By End Use

• Hospitals
• Diagnostics centers
• Specialty clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE